NEW YORK,  February 4,  2013  - Delcath  Systems,  Inc. (NASDAQ:  DCTH)  today 
announced that the Institut für  das Entgeltsystem im Krankenhaus (InEk),  the 
German federal reimbursement agency,  has established a reimbursement  pathway 
for the treatment of patients with  liver metastases with the Delcath  Hepatic 
CHEMOSAT^® Delivery System  for melphalan hydrochloride.  The decision by  the 
InEK followed  an  endorsement  by the  German  Radiology  Association,  which 
prompted 47 cancer centers throughout Germany to submit applications under the
Neue Untersuchungs- und  Behandlungsmethoden (NUB) scheme  for new  technology 
reimbursement at specific hospitals. The Value 4 status given to the  CHEMOSAT 
procedure, while  not  mandating reimbursement,  allows  participating  cancer 
centers to negotiate  reimbursement coverage for  the CHEMOSAT procedure  with 
all insurers  serving  their  region.  Under  the  NUB  scheme,  reimbursement 
pathways will potentially be available for treatment with CHEMOSAT  regardless 
of primary cancer origin.

Eamonn P. Hobbs, President & CEO of Delcath said, "This is excellent news  for 
both patients in Germany and Delcath, as it represents a significant  positive 
step in our  efforts to fully  commercialize CHEMOSAT in  Europe. This is  the 
first reimbursement mechanism for our procedure in Germany, the biggest market
for CHEMOSAT  in  the  European  Union.  It is  important  to  note  that  the 
application for  coverage  was  supported  by 47  cancer  centers  across  the 
country, which we believe speaks to the medical need physicians in Germany see
for CHEMOSAT.  We  will  continue  to  work  closely  with  the  participating 
hospitals to  achieve reimbursement  with the  insurers. With  a direct  sales 
force in place and training of the  additional centers in Germany on the  way, 
we are now in a good position to begin growing this market for CHEMOSAT."

About Delcath Systems

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company
focused on  oncology.  Delcath's  proprietary system  for  chemosaturation  is 
designed to administer high dose chemotherapy and other therapeutic agents  to 
diseased organs  or  regions  of  the body,  while  controlling  the  systemic 
exposure of those agents. The Company's  initial focus is on the treatment  of 
primary and  metastatic liver  cancers. In  2010, Delcath  announced that  its 
randomized Phase 3 clinical trial for patients with metastatic melanoma in the
liver had  successfully  achieved the  study's  primary endpoint  of  extended 
hepatic progression-free  survival. The  Company  also completed  a  multi-arm 
Phase 2 trial to treat other liver cancers. The Company obtained authorization
to affix  a CE  Mark for  the  Generation Two  CHEMOSAT® delivery  system  for 
melphalan hydrochloride in April 2012. The right to affix the CE mark  allows 
the Company to market and sell the CHEMOSAT system for melphalan hydrochloride
in Europe. In October 2012, the  Company satisfied all of the requirements  to 
affix the  CE  Mark  to  the  Hepatic  CHEMOSAT  Delivery  System  device  for 
intra-hepatic arterial delivery and  extracorporeal filtration of  doxorubicin 
hydrochloride injection,  providing  a  regulatory pathway  for  the  CHEMOSAT 
Delivery System to deliver and filter  doxorubicin for countries in Asia  that 
accept the CE Marking as part of their national regulatory requirements.  The 
Company has not yet received FDA approval for commercial sale of its system in
the United  States.  The  Company's  NDA has  been  accepted  for  filing  and 
substantive review  by  the  FDA.  For more  information,  please  visit  the 
Company's website at

Private Securities Litigation Reform  Act of 1995 provides  a safe harbor  for 
forward-looking statements made  by the Company  or on its  behalf. This  news 
release contains  forward-looking statements,  which  are subject  to  certain 
risks and uncertainties  that can  cause actual results  to differ  materially 
from those described. Factors that may cause such differences include, but are
not limited  to, uncertainties  relating to:  whether each  of the  47  cancer 
centers in Germany will successfully  negotiate and receive reimbursement  for 
the CHEMOSAT procedure in their region  and the amount of reimbursement to  be 
provided, patient  outcomes  using the  CHEMOSAT  system in  the  EU,  patient 
outcomes using the chemosaturation system under the EAP, timing of completion
of the  FDA's review  of our  NDA, the  extent to  which the  FDA may  request 
additional information or data and our ability to provide the same in a timely
manner, acceptability of the Phase 1, 2 and 3 clinical trial data by the  FDA, 
FDA approval  of the  Company's NDA  for the  treatment of  ocular  metastatic 
melanoma to  the liver,  adoption, use  and resulting  sales, if  any, in  the 
United States, adoption,  use and resulting  sales, if any,  for the  CHEMOSAT 
system to deliver and filter melphalan in the EEA, our ability to successfully
commercialize  the   chemosaturation  system   and   the  potential   of   the 
chemosaturation system as a treatment for patients with primary and metastatic
disease in the  liver, market acceptance  of the Gen  Two CHEMOSAT system  and 
patient  outcomes  using  the  same,   approval  of  the  current  or   future 
chemosaturation system for delivery  and filtration of melphalan,  doxorubicin 
or other chemotherapeutic agents for various  indications in the US and/or  in 
foreign markets, actions by the FDA or other foreign regulatory agencies,  our 
ability to  successfully enter  into  strategic partnership  and  distribution 
arrangements in foreign markets including Australia and key Asian markets  and 
timing an revenue, if any, of the same, the approval of the Hepatic  CHEMOSAT 
Delivery System device to deliver and filter doxorubicin in key Asian markets
and patient outcomes using the same,  our ability to obtain reimbursement  for 
the CHEMOSAT  system, uncertainties  relating  to the  timing and  results  of 
research and development  projects, uncertainties relating  to the timing  and 
results of future clinical trials, and uncertainties regarding our ability  to 
obtain financial  and  other  resources  for  any  research,  development  and 
commercialization activities. These  factors, and others,  are discussed  from 
time to time in our filings  with the Securities and Exchange Commission.  You 
should not place  undue reliance  on these  forward-looking statements,  which 
speak only  as of  the  date they  are made.  We  undertake no  obligation  to 
publicly update or revise these  forward-looking statements to reflect  events 
or circumstances after the date they are made.

Contact Information:
Investors:                  Financial Media EU Consumer/Medical Media
Gregory Gin/Patty Eisenhaur Janine McCargo  Julie Johnson
EVC Group                  EVC Group       Bliss Integrated
646-445-4801/951-316-0577   646-688-0425    503-883-9103


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Delcath Systems, Inc via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.